Marius Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Marius Pharmaceuticals is a clinical-stage biotech company developing novel oral hormone therapies, with its flagship product, KYZATREX, approved and commercially available in the US and Canada for testosterone replacement therapy (TRT) in adult men with certain medical conditions. The company is actively researching broader applications of testosterone therapy in comorbidities like obesity and type 2 diabetes, as well as exploring its potential in women's health. Led by CEO Shalin Shah, Marius combines a commercial product with an ambitious R&D pipeline, positioning itself at the intersection of metabolic health and endocrinology.

EndocrinologyMetabolic DisordersMen's HealthWomen's Health

Technology Platform

Proprietary oral drug delivery platform for testosterone undecanoate, utilizing a self-emulsifying system designed for lymphatic absorption to bypass first-pass liver metabolism.

Opportunities

The primary opportunity is to expand the use of its oral testosterone therapy beyond classic hypogonadism into large adjacent markets like metabolic disease (obesity, type 2 diabetes) and women's health.

Successfully demonstrating metabolic benefits could redefine testosterone as a mainstream therapy for chronic conditions.

The partnership with Hims & Hers provides a direct channel to a large patient base in the growing telehealth sector.

Risk Factors

Key risks include regulatory hurdles in expanding the drug's label, particularly for age-related decline and new indications, which require costly and uncertain clinical trials.

The company faces intense competition in the established TRT market from large pharmaceutical companies.

There are also inherent safety concerns associated with testosterone therapy, including cardiovascular risks, which could impact commercialization.

Competitive Landscape

Marius competes in the crowded testosterone replacement therapy market against dominant products like AbbVie's AndroGel (transdermal), Endo's Aveed (injection), and various generic options. Its key differentiation is the oral formulation (KYZATREX), competing primarily with other oral agents like Clarus Therapeutics' Jatenzo. For its investigational metabolic indications, it would compete with a vast array of diabetes and obesity drugs, positioning itself as a novel hormonal/metabolic modulator rather than a direct competitor.

More companies in Small Molecule Drugs →More companies in United States →